ConductScience.org, home

Paper9083333

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.

Rentsch KM and 4 others. Br J Cancer, 1997. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Papers, record 9083333. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9083333

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
PubMed
Journal
Br J Cancer
PubMed
Year
1997
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2019-05-15
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rentsch KMK M
2Horber DHD H
3Schwendener RAR A
4Wunderli-Allenspach HH
5Hänseler EE

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
MitoxantroneMajor topic
Animals
Female
Humans
Mice
Mice, Inbred Strains
Neoplasm Transplantation
Neoplasms, Experimental
Tissue Distribution
Transplantation, Heterologous

Source PubMed

Download CSV of topics

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11676658Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations.Drug Metab Dispos1991https://conductscience.org/library/papers/1676658PubMed
22013113Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/2013113PubMed
31764871Pharmacokinetic optimisation of anticancer therapy.Clin Pharmacokinet1991https://conductscience.org/library/papers/1764871PubMed
41737351Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.Cancer Res1992https://conductscience.org/library/papers/1737351PubMed
51686230Evidence for oxidative activation of mitoxantrone in human, pig, and rat.Drug Metab Dispos1991https://conductscience.org/library/papers/1686230PubMed
61568796Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid.Int J Cancer1992https://conductscience.org/library/papers/1568796PubMed
71596882Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.Cancer Res1992https://conductscience.org/library/papers/1596882PubMed
88321835Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.Pharm Res1993https://conductscience.org/library/papers/8321835PubMed
98998559Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography.J Chromatogr B Biomed Appl1996https://conductscience.org/library/papers/8998559PubMed
101711446Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs1991https://conductscience.org/library/papers/1711446PubMed
116375887Detection and quantification of mitoxantrone in human organs. A case report.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6375887PubMed
123978648Disposition of mitoxantrone in cancer patients.Cancer Res1985https://conductscience.org/library/papers/3978648PubMed
133979268Comment on mitoxantrone.Drug Intell Clin Pharm1985https://conductscience.org/library/papers/3979268PubMed
143839135Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential.Biochim Biophys Acta1985https://conductscience.org/library/papers/3839135PubMed
154040505Pharmacology of mitoxantrone: mode of action and pharmacokinetics.Invest New Drugs1985https://conductscience.org/library/papers/4040505PubMed
163484382Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3484382PubMed
173941019Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.Int J Cancer1986https://conductscience.org/library/papers/3941019PubMed
183964703Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.Biochim Biophys Acta1986https://conductscience.org/library/papers/3964703PubMed
193521429Mitoxantrone: a new anticancer drug with significant clinical activity.Ann Intern Med1986https://conductscience.org/library/papers/3521429PubMed
203768871Human autopsy tissue concentrations of mitoxantrone.Cancer Treat Rep1986https://conductscience.org/library/papers/3768871PubMed

See all 24 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
27601896
Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
Int J Nanomedicine2016https://conductscience.org/library/papers/27601896PubMed
24961369Ultrasound-triggered disruption and self-healing of reversibly cross-linked hydrogels for drug delivery and enhanced chemotherapy.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/24961369PubMed
23049558Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine.Adv Hematol2012https://conductscience.org/library/papers/23049558PubMed
22451016A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.AAPS J2012https://conductscience.org/library/papers/22451016PubMed
20369276Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.Pharm Res2010https://conductscience.org/library/papers/20369276PubMed
11494116Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone.Neoplasia2001https://conductscience.org/library/papers/11494116PubMed
10933074Applications of magnetic resonance in model systems: cancer therapeutics.Neoplasia2000https://conductscience.org/library/papers/10933074PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9083333

GET https://conductscience.org/api/papers/v1/9083333/references?page=2